VANCOUVER, BC - June 11, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today reported financial results and the filing of the Company’s unaudited interim financial statements as of and for the three- and nine-month periods ended April 30, 2026 (the “Financial Statements”), the management’s discussion and analysis (“MD&A”), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO”) relating to the Financial Statements (collectively, the “Interim Filings”). All values are in Canadian dollars unless stated otherwise.

“Since the beginning of the year, our focus has been on securing the capital necessary to support Helix’s near-term operating and development objectives,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “With the successful completion of our recent private placement, we have made substantial progress toward our objective of establishing approximately twelve months of operating runway. This financing strengthens our ability to execute against our strategic priorities, including ongoing preparations for a U.S. exchange listing as we work to expand access to capital, advance L-DOS47 toward the clinic, and create long-term shareholder value.”

Financial Highlights:

- The Company incurred a net and total comprehensive loss from operations of $671,000 for the three months ended April 30, 2026, and a loss of $2,374,000 for the nine months ended April 30, 2026, versus a net loss of $1,544,000 and $4,255,000 for the three and nine months ended April 30, 2025, respectively. The decrease in net loss was primarily due to reduced research and development expenses and the closing out of the Company’s LDOS006 clinical study, partially offset by an increase in operating, general and administrative expenses associated with accounting, tax, legal, and consulting fees.

- The net and total comprehensive loss for the reporting period corresponds to a loss of $0.01 and $0.03 per common share for the three and nine months ended April 30, 2026, respectively, versus a loss of $0.03 and $0.08 per common share for the three and nine months ended April 30, 2025, respectively.

- The Company had cash of $2,842,000 as of April 30, 2026, up from $65,000 as of July 31, 2025.

- During the quarter, the Company received $3,673,000 in cash proceeds related to a private placement of unsecured convertible debentures. The Company issued convertible debentures totaling $3,673,000 to the subscribers subsequent to quarter-end, bearing interest at 25% per annum and with maturity date 14 months from the Closing Date, being July 27, 2027. The principal is convertible at $1.42 per common share, and accrued interest is convertible at the greater of (i) $1.42 and (ii) the 5-day VWAP less the TSX-permitted discount. As at April 30, 2026, the debentures had not yet been issued, and the Company had not become a party to the contractual terms of the instruments. Accordingly, the proceeds have been recorded as subscription advances in the Financial Statements, presented as a currently liability on the statement of financial position.

- The Company continues to evaluate financing and capital markets alternatives to support its ongoing operations and future growth initiatives. As part of these efforts, the Company is working with legal advisors in connection with the filing of a base shelf prospectus and is engaged in discussions with prospective investment banking partners regarding future financing and capital markets opportunities. The Company is also assessing opportunities to broaden its investor base and increase access to U.S. capital markets, including the potential for a future listing on a U.S. securities exchange.

The Interim Filings

For more information, please see the Interim Filings, which are available on the Company’s profile at www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

For more information, please contact:

Helix BioPharma Corp.
789 West Pender Street, Suite 480
Vancouver, BC V6C 1H2
Tel: +1 857 208 7687
Thomas Mehrling, MD, PhD, Chief Executive Officer
corporate@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to L-DOS47, LEUMUNA, and GEMCEDA, as well as its activities relating to financing and listing on a U.S. securities exchange. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026.